Id: | acc3316 |
Group: | 2sens |
Protein: | IkappaBalpha |
Gene Symbol: | NFKBIA |
Protein Id: | P25963 |
Protein Name: | IKBA_HUMAN |
PTM: | phosphorylation |
Site: | unclear |
Site Sequence: | |
Disease Category: | Cancer |
Disease: | Colorectal Cancer |
Disease Subtype: | |
Disease Cellline: | SW620 |
Disease Info: | |
Drug: | As4O6 |
Drug Info: | "As4O6 is a chemical compound that may be used as a drug. In the field of medicine, it might have specific therapeutic applications. " |
Effect: | modulate |
Effect Info: | As4O6 inhibits the growth of SW620 cells in a dose-dependent manner. As4O6 can inhibit the activation of NF-κB and suppress the phosphorylation of inhibitory κBα (IκBα) induced by tumor necrosis factor (TNF) stimulation. |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 25845556 |
Sentence Index: | 25845556_5-6 |
Sentence: | "The cytotoxicity assay revealed that As4O6 inhibited the growth of SW620 cells in a dose-dependent manner, and the half maximal inhibitory concentration (IC50) was ~1 microM after a 48 h treatment. As4O6 suppressed NF-kappaB activation and suppressed inhibitory kappaBalpha (IkappaBalpha) phosphorylation stimulated by tumor necrosis factor (TNF)." |
Sequence & Structure:
MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
- | - | N | Autosomal dominant anhidrotic ectodermal dysplasia | Phosphorylation | 14523047 |
- | - | U | Colorectal cancer | Ubiquitination | 31685801 |
- | - | U | Squamous cell carcinoma | Ubiquitination | 35128752 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.